Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126749011 | 12674901 | 1 | I | 201608 | 20160819 | 20160823 | 20160823 | PER | US-009507513-1608USA010438 | MERCK | 63.53 | YR | M | Y | 0.00000 | 20160823 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126749011 | 12674901 | 1 | PS | INTRON A | INTERFERON ALFA-2B | 1 | Subcutaneous | 2.4 ML, MONDAY, WEDNESDAY, FRIDAY; STRENGTH REPORTED AS 25 MU | L041049 | 103132 | 2.4 | ML | POWDER FOR INJECTION | TIW | |||||
| 126749011 | 12674901 | 2 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 3 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | TABLET | ||||||||||
| 126749011 | 12674901 | 4 | C | CYANOCOBALAMIN. | CYANOCOBALAMIN | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 5 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 6 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 7 | C | ECHINACEA PURPUREA | ECHINACEA PURPUREA | 1 | 0 | ORAL SOLUTION | |||||||||||
| 126749011 | 12674901 | 8 | C | OMEGA-3 MARINE TRIGLYCERIDES | FISH OIL | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 9 | C | FLAXSEED | FLAX SEED | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 10 | C | HYDROCHLOROT | HYDROCHLOROTHIAZIDE | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 11 | C | INVOKANA | CANAGLIFLOZIN | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 12 | C | MAG OXIDE | MAGNESIUM OXIDE | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 13 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 14 | C | METOCLOPRAMIDE. | METOCLOPRAMIDE | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 15 | C | VICTOZA | LIRAGLUTIDE | 1 | 0 | ||||||||||||
| 126749011 | 12674901 | 16 | C | ASCORBIC ACID. | ASCORBIC ACID | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126749011 | 12674901 | 1 | Skin cancer |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126749011 | 12674901 | Arthralgia | |
| 126749011 | 12674901 | Mouth haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126749011 | 12674901 | 1 | 20160505 | 0 |